ScanTech AI Systems Appoints Security Industry Veteran Brad Buswell as Chairman of the Board
'On behalf of the entire ScanTech AI team, I would like to thank Karl Brenza for his steady leadership and instrumental role in navigating the Company's transformation into a publicly traded enterprise,' said Dolan Falconer, Chief Executive Officer and President at ScanTech AI. 'We are equally honored to welcome Brad Buswell as our new Chairman. Brad brings unparalleled experience in both public and private sector security innovation, and his strategic acumen will be of great value as we continue to expand our market share and deepen our global footprint.'
Mr. Buswell is a seasoned executive with more than 30 years of leadership in national security, aviation screening, and advanced detection technologies. He most recently served as Senior Vice President of Security Enterprise Solutions at Leidos (NYSE: LDOS), where he helped drive innovation in aviation and critical infrastructure protection. Prior to Leidos, Mr. Buswell held executive leadership roles, including President and CEO of Morpho Detection and President of Rapiscan North America. His public sector experience includes his appointment as Deputy Under Secretary for Science and Technology at the U.S. Department of Homeland Security, where he oversaw strategic R&D efforts supporting the Transportation Security Administration, Customs and Border Protection, and other DHS components. Mr. Buswell is also a 20-year veteran of the U.S. Navy and holds degrees from the U.S. Naval Academy and George Washington University.
'I am deeply honored by the appointment as Chairman of the Board of Directors at such an exciting juncture in the Company's growth,' said Mr. Buswell. 'ScanTech AI's cutting-edge AI and CT-based technologies are redefining the standards for non-intrusive security screening. I look forward to supporting the executive team and fellow board members as we build long-term value for stockholders, customers, and global partners.'
About ScanTech AI
ScanTech AI Systems Inc. (Nasdaq: STAI) has developed one of the world's most advanced non-intrusive 'fixed-gantry' CT screening technologies. Utilizing proprietary artificial intelligence and machine learning capabilities, ScanTech AI's state-of-the-art scanners accurately and quickly detect hazardous materials and contraband. Engineered to automatically locate, discriminate, and identify threat materials and items of interest, ScanTech AI's solutions are designed for use in airports, seaports, borders, embassies, corporate headquarters, government and commercial buildings, factories, processing plants, and other facilities where security is a priority.
For more information, visit www.scantechais.com and investor.scantechais.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the U.S. Securities Exchange Act of 1934, as amended ('Exchange Act'), including statements regarding ScanTech AI's management team's expectations, hopes, beliefs, intentions, plans, prospects or strategies regarding the future, including possible business partnerships, revenue growth and financial performance, product expansion and services. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Additionally, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'ongoing,' 'target,' 'seek' or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this press release are based on the current expectations and beliefs made by the management of ScanTech AI, in light of their respective experience and their perception of historical trends, current conditions and expected future developments and their potential effect on ScanTech AI, as well as other factors they believe are appropriate under the circumstances. There can be no assurance that future developments affecting ScanTech AI will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the parties) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including product and service acceptance, regulatory oversights, research and development success, and that ScanTech AI will have sufficient capital to operate as anticipated. Should one or more of these risks of uncertainties materialize, or should any of the assumptions of ScanTech AI prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Additional factors that could cause actual results to differ are discussed under the heading 'Risk Factors' and in other sections of the filings of ScanTech AI (and its predecessor, Mars) with the U.S. Securities and Exchange Commission (the 'SEC'), and in the current and periodic reports filed or furnished by ScanTech AI (and its predecessor, Mars) from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on the information available to ScanTech AI as of the date hereof, and ScanTech AI assumes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as may otherwise be required under applicable securities laws.
Attachment
Brad Buswell, Chairman of the Board of Directors
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
15 minutes ago
- Globe and Mail
oneZero makes the Inc. 5000 list of America's fastest-growing private companies for fourth consecutive year
NEW YORK, Aug. 12, 2025 /CNW/ -- Inc., the leading media brand and playbook for the entrepreneurs and business leaders shaping our future, today announced that oneZero Financial Systems (oneZero) has reached the 2025 Inc. 5000 list of the fastest-growing private companies in America. This is the fourth consecutive year that oneZero has made the prestigious ranking.
Globe and Mail
15 minutes ago
- Globe and Mail
Citizens Financial Group Names Aunoy Banerjee of Barclays as Chief Financial Officer
Citizens Financial Group, Inc. (NYSE: CFG) today announced the appointment of Aunoy Banerjee as Executive Vice President and Chief Financial Officer. He will serve on the company's Executive Committee and report to Chairman and CEO Bruce Van Saun. Banerjee joins Citizens from Barclays, where he currently serves as CFO of Barclays Bank PLC, leading a large, global, multifunctional team supporting multiple lines of business including U.S. Consumer, Global Corporate and Investment Banking, and Private Bank and Wealth Management. Banerjee will join Citizens on October 24. As previously announced, current CFO John Woods will depart the bank on August 15. Chris Emerson, EVP and Head of Corporate Planning & Enterprise Finance, will serve as CFO during the interim period. "Aunoy is a seasoned leader with a broad background and strong record of accomplishment over his career,' said Van Saun. 'His experience in leading finance functions at multiple large financial institutions and overseeing highly complex transformation and optimization programs positions him well to have immediate impact as we execute our ambitious growth and transformation agenda.' Said Banerjee: 'I could not be more excited to be joining Citizens to help drive sustainable growth and value for all of its stakeholders. The Bank has been on an exciting and transformational journey, and I look forward to partnering with Bruce and the leadership team to help take Citizens to the next level.' A 25-year financial services veteran, Banerjee will have responsibility for the Financial Planning and Analysis, Business Line Finance Groups, Controller, Investor Relations, Treasury, Tax, and Capital Management functions, as well as Property & Procurement. Prior to Barclays, Banerjee served in a number of increasingly responsible finance and transformation roles at State Street over eight years, most recently as Head of Investments & Third Party Management and Chair of State Street India. He also served as Chief Transformation Officer and prior to that ran Corporate FP&A and oversaw the CFO functions within its business units. He previously spent 11 years at Citi with several roles of increasing importance, including Business Unit CFO for Capital Markets and Securities Services, Finance Head of CCAR and Head of Corporate Forecasting and Planning. He began his professional career at General Electric as part of its Finance Management Leadership Program. Highlights of Banerjee's broad experience include overseeing a £1.1 trillion balance sheet at Barclays Bank PLC and co-leading the firm's sweeping investment bank simplification initiative. At State Street, he oversaw the firm's $100 billion-plus investment portfolio and its balance sheet funding position. Additionally, as Chief Transformation Officer, he led an enterprise-wide transformation aimed at simplifying operations, increasing operating margin and productivity, and boosting both organic and inorganic growth. Banerjee holds a Master of Business Administration degree from the University of Rochester Simon School of Business and a Bachelor of Science degree from St. Stephen's College at the University of Delhi. About Citizens Financial Group, Inc. Citizens Financial Group, Inc. is one of the nation's oldest and largest financial institutions, with $218.3 billion in assets as of June 30, 2025. Headquartered in Providence, Rhode Island, Citizens offers a broad range of retail and commercial banking products and services to individuals, small businesses, middle-market companies, large corporations and institutions. Citizens helps its customers reach their potential by listening to them and by understanding their needs in order to offer tailored advice, ideas and solutions. In Consumer Banking, Citizens provides an integrated experience that includes mobile and online banking, a full-service customer contact center and the convenience of approximately 3,100 ATMs and approximately 1,000 branches in 14 states and the District of Columbia. Consumer Banking products and services include a full range of banking, lending, savings, wealth management and small business offerings. In Commercial Banking, Citizens offers a broad complement of financial products and solutions, including lending and leasing, deposit and treasury management services, foreign exchange, interest rate and commodity risk management solutions, as well as loan syndication, corporate finance, merger and acquisition, and debt and equity capital markets capabilities. More information is available at or visit us on X (formerly Twitter), LinkedIn or Facebook . Cautionary Statement About Forward-Looking Statements This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about our expectations regarding the appointment of a new Citizens chief financial officer. Any statement that does not describe historical or current facts is a forward-looking statement. These statements often include the words 'believes,' 'expects,' 'anticipates,' 'estimates,' 'intends,' 'plans,' 'goals,' 'targets,' 'initiatives,' 'potentially,' 'probably,' 'projects,' 'prospects,' 'outlook,' 'guidance' or similar expressions or future or conditional verbs such as 'may,' 'will,' 'likely,' 'should,' 'would,' and 'could.' Forward-looking statements are based upon the current beliefs and expectations of management, and on information currently available to management. Our statements speak as of the date hereof, and we do not assume any obligation to update these statements or to update the reasons why actual results could differ from those contained in such statements in light of new information or future events. We caution you, therefore, against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. More information about factors that could cause actual results to differ materially from those described in the forward-looking statements can be found under 'Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the United States Securities and Exchange Commission. View source version on
Globe and Mail
15 minutes ago
- Globe and Mail
Johnson & Johnson EVP Sells JNJ Shares Worth $3 Million
John C. Reed, Executive Vice President, Innovative Medicine and R&D of Johnson & Johnson (NYSE:JNJ), executed an open market sale of 19,137 shares as disclosed in a Form 4 filed July 18, 2025. Transaction summary Metric Value Shares traded 19,137 Transaction value $3.13 million, as reported in the SEC Form 4 filing dated July 18, 2025 1-year performance (as of July 18) 8% total return over the past year (calendar year basis) Key questions How does this transaction compare to John C. Reed's historical trading activity? This sale is smaller than Reed's historical median transaction size of 36,239 shares, and follows a recent trend of reduced trade volumes and more frequent selling over the past year, with only 20% of his trades classified as buys over the past 12 months. How does the transaction price relate to current market pricing? Shares were sold at an average price of $163.55, approximately 0.5% below the $164.36 closing price as of July 21, 2025, indicating the sale occurred at a slight discount to the latest market price. What is the context of this transaction in relation to Johnson & Johnson's recent performance? Johnson & Johnson shares delivered 8% total return in one year as of the transaction reporting date. The company maintains a large market capitalization and leadership in the healthcare sector, suggesting the sale does not coincide with pronounced negative price momentum. Company overview Metric Value Market capitalization $417.4 billion Revenue (TTM) $90.6 billion Net income (TTM) $22.7 billion Dividend yield 3.0% Company snapshot Johnson & Johnson generates revenue through two segments: innovative medicine (pharma) and medtech (medical devices). The company operates a diversified business model focused on research, development, manufacturing, and global distribution of healthcare products, with a balanced mix of prescription medicines and medical devices. Johnson & Johnson is a Dividend King, having increased its dividend for over 60 consecutive years. Foolish take Once known primarily for its consumer health brands such as Tylenol and Listerine, Johnson & Johnson made a major strategic move in 2023 when it spun off its consumer health business into a separate publicly-listed company, Kenvue. J&J is now a healthcare behemoth, with two diversified businesses that cover two of the most important areas of healthcare. Its innovative medicine segment focuses on oncology, immunology, and neuroscience, owns top medicine brands like Darzalex, Stelara, and Imbruvica, and accounted for 64% of J&J's total sales in fiscal 2024. Medtech, meanwhile, makes medical equipment and technologies for cardiology, surgery, and vision. Between the two businesses, J&J owns 26 products or platforms generating over $1 billion in annual sales each. Despite Stelara's loss of exclusivity, J&J continues to deliver. In its second quarter, J&J reported 5.8% growth in net sales. In innovative medicine, oncology continues to grow at a steady pace, while Spravato is growing rapidly. Sales from Spravato, a nasal spray for treatment-resistant depression in adults, jumped 53% in Q2. Strong Q2 performance and progress in new product pipeline even encouraged J&J management to boost its full-year guidance. It now expects operational sales (sales excluding the impact of currency) to grow by 4.8% at the midpoint versus its previous forecast of 3.8% and adjusted earnings per share by 8.7% at the midpoint versus 6.2%. I believe investors shouldn't read much into insider sales like Reed's transaction, and continue to buy and hold this magnificent dividend stock. Glossary Form 4: A required SEC filing disclosing insider trades by company officers, directors, or major shareholders. Open market sale: The sale of securities on a public exchange, rather than through private transactions or company programs. Insider trading activity: Buying or selling a company's stock by its executives, directors, or employees with access to nonpublic information. Median transaction size: The middle value of all transaction sizes, used to measure typical trade volume for an individual. Total return: The investment's price change plus all dividends and distributions, assuming those payouts are reinvested. Dividend yield: Annual dividend payments divided by the stock's current price, shown as a percentage. TTM: The 12-month period ending with the most recent quarterly report. Market capitalization: The total market value of a company's outstanding shares. Pharmaceuticals: Prescription drugs and medicines developed, manufactured, and sold by healthcare companies. Medtech: Medical technology products, including devices and equipment used in healthcare settings. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,060%* — a market-crushing outperformance compared to 182% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you joinStock Advisor. See the stocks » *Stock Advisor returns as of August 11, 2025 Neha Chamaria has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Kenvue. The Motley Fool recommends Johnson & Johnson and recommends the following options: long January 2026 $13 calls on Kenvue. The Motley Fool has a disclosure policy.
